As a leader in antibody production and manufacture, Creative Biolabs provides high quality bispecific antibodies (BsAbs) targeting different receptors. With our most devoted scientists, we are confident to deliver you unique BsAb with high affinity and specificity to meet your project development.
In the field of biology/pharmacology, a receptor is referred to as a membrane protein that receives signals upon binding of signal molecules (ligands) and passes on the “message” by triggering subsequent intracellular or intercellular responses. Depends on the specific location on the membrane, receptors can be classified into three groups: cell surface receptors, cytoplasmic receptors, and nuclear receptors. A ligand can be a protein/peptide, or a small molecule such as a hormone, toxin, or virus or microbe surface protein. Each receptor responds to a specific ligand (or specific ligands) and triggers a specific biological pathway. Ligand-receptor signaling controls every aspect of cell activity and thus is a popular type of drug targets. In recent years, BsAbs have gained more and more attention as therapeutic agents targeting receptors.
Figure 1. Co-targeting HER family members by BsAbs.
BsAbs are artificial antibodies and are capable of binding to two different epitopes on two different ligands. This dual binding activity enables BsAbs to block different pathways, reduce the possibility of escaping mechanisms, and improve the therapeutic efficacy. The interaction between vascular endothelial growth factor (VEGF) and its receptor VEGFR is an important signaling pathway involved in not only vasculogenesis but also angiogenesis. Vasculogenesis and angiogenesis are often upregulated in tumor development and ocular diseases.
Several BsAbs have been produced to block these receptor signaling pathways in order to control the diseases. For example, a bispecific diabody and a diabody-Fc fusion protein were designed to bind VEGFR 2 and VEGFR 3, which blocks the binding of VEGF and VEGF-C and inhibits activation of the receptors. Similarly, a diabody-Fc fusion protein was generated to target epidermal growth factor receptor (EGF receptor) and insulin-like growth factor 1 (IGF-1) receptor. These receptors are important for cancer development. Therefore this BsAb blocks both signaling pathways and inhibites subsequent signal transduction. Other BsAb formats designed to target different receptors include but not limit to scFv-IgG fusion proteins, scFv-HSA fusion proteins, diabody, and DART. Their targets feature in cell-surface receptors important for cancer development, allergies, disorders due to unwanted inflammatory reactions, and infections. Famous targets include EGFR2, HER2, IGF1-R, VEGFR2, VEGFR3, and CD22.
Creative Biolabs is always standing in a leading position in the field of BsAb services. Advanced antibody engineering platforms have been developed in Creative Biolabs to provide our customers high-quality BsAbs. Our research team can help each customer design and/or screen for the most suitable BsAb product for his studies.
1. Zhu, Y.; et al. Multifunctional receptor-targeting antibodies for cancer therapy. The Lancet Oncology. 2015, 16(15): e543-e554.
2. Kontermann R. E. Dual targeting strategies with bispecific antibodies. MAbs. 2012, 4(2): 182-197.